The board of directors pharmaceutical company Allergan plc (NYSE:AGN) approved a dividend of USD0.72 per ordinary share for the first quarter of 2018, the company declared on Friday.
This cash dividend is due on 28 March 2018 to shareholders of record at the close of business as of 28 February 2018.
In addition, the company has scheduled its 2018 Annual General Meeting of Shareholders for 2 May 2018 in Dublin, Ireland. The board has set the close of business on 6 March 2018 as the record date for determining shareholders eligible to vote at the meeting.
Headquartered in Dublin, Ireland, Allergan is focused on developing, manufacturing and commercialising branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
Bactiguard Holding widens loss in Q3 2018
AstraZeneca divests rights of Alvesco, Omnaris and Zetonna to Covis Pharma
Vitrolife's net income up in Q3 2018
Real-World Evidence Study Shows Empagliflozin Reduces Risk for Hospitalisation for Heart Failure
Hansa Medical widens loss in Q3 2018
Grünenthal to acquire European rights to Nexium and global (ex US and Japan) rights to Vimovo
Allergan's board reports USD0.72 per ordinary share dividend
Merck's board approves higher Q4 dividend & expanded share repurchase plan
Onxeo reports Q3 2018 consolidated revenues and provides business update
Orion and Bayer announce completion of phase III trial of darolutamide; primary end point met
Walgreens Boots Alliance's board authorises USD0.44 per share dividend
Illumina posts higher GAAP net income of USD199m for Q3 fiscal 2018